Global Digital Dose Inhaler Market Overview:
Digital Dose Inhaler is the medical device that is used to cure respiratory diseases. Digital Dose Inhaler have inbuilt digital sensors that helps in recording the usage of an inhaler at the time of access and provides easier access to the user as it can be connected via Bluetooth to their mobile phone. It also gives the information regarding previous dose taken and gives suggestion accordingly. Digital Dose Inhaler can generate alerts for the daily dosage for the user. Advantage over conventional inhalers technological advancements, improving adherence to inhalers, linking with tele-health, and due to extensive use of smart computing devices, the demand for digital dose inhalers is growing rapidly. Data security concern related to security devices, regulating government policies for the use of healthcare devices, and also limited availability of these products in potential emerging regions will hamper the growth of the market.
- Presence of Large Population Suffering from Acute and Chronic Asthma Owing to Numerous Factors Like Air Pollution, Smoking, and Unhealthy Lifestyle
- Technological Advancement in Healthcare Treatments Facilitating Effective Asthma Management
- Availability of Medication Data on Mobile App Provides Easier Access
- Growing Demand for Advanced Tele Medical Devices
- Unawareness about the Easy and Affordable Accessibility of Asthma Treatment in Many Locations
- Continuously Increasing Air Pollution
- Growing Fad of Smoking Which Leads Respiratory Diseases
- Improper Inhaler Usage Especially Amongst Children Poses a Challenge and can Contribute to Poor Asthma Control
The digital dose inhaler market is moderately fragmented with the presence of many players worldwide. Some of the leading players are adopting some organic and inorganic strategies such as a merger, acquisition, expansion, new product launches, among others in order to gain leading share within the market. Owing to the supportive government regulations there are massive opportunities emerging for the new entrants.
Some of the key players profiled in the report are 3M (United States), Merck & Co., Inc. (United States), Novartis AG (Switzerland), GlaxoSmithKline (United Kingdom), Adherium Limited (New Zealand), AstraZeneca (England), Cohero Health (United States), Propeller Health (United States), Boehringer Ingelheim GmbH (Germany) and Gecko Health Innovations Inc (United States). Additionally, following companies can also be profiled that are part of our coverage like Omron Corporation (Japan), Sunovion Pharmaceuticals Inc. (United States) and Inspiro Medical Ltd. (Israel). Analyst at AMA Research see United States Players to retain maximum share of Global Digital Dose Inhaler market by 2026. Considering Market by Nature, the sub-segment i.e. Branded will boost the Digital Dose Inhaler market. Considering Market by End Use, the sub-segment i.e. Chronic Obstructive Pulmonary Disease will boost the Digital Dose Inhaler market.
Latest Market Insights:
In November 2019, Novartis announced that it has entered into an agreement and plan of merger with the medicines company (United States) and In January 2018, GlaxoSmithKline successfully completed its acquisition of Tesaro, an oncology-focused company through its wholly-owned subsidiary Adriatic acquisition corporation
In January 2019, the United States Food and Drug Administration (USFDA) announced its approval for the world’s first digital inhaler “Proair Digihaler” (Teva pharmaceutical industries) for the management of asthma.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Digital Dose Inhaler market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Digital Dose Inhaler market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceuticals Companies, Medical Research Laboratories, Investors, Distributors/Traders, Importers/Exporters, Regulatory and Government Bodies, Downstream Vendors, Up-Stream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.